Bethanidine
Chemical compound
- C02CC01 (WHO)
- 3-benzyl-1,2-dimethylguanidine
- 55-73-2
N
- 2368
- 7618
- DB00217
Y
- 2278
Y
- W8S3YM7AUU
- D01603
N
- CHEBI:37937
Y
- ChEMBL1201260
N
- DTXSID7022677
- Interactive image
- N(=C(/NCc1ccccc1)NC)\C
InChI
- InChI=1S/C10H15N3/c1-11-10(12-2)13-8-9-6-4-3-5-7-9/h3-7H,8H2,1-2H3,(H2,11,12,13)
Y
- Key:NIVZHWNOUVJHKV-UHFFFAOYSA-N
Y
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Bethanidine (or betanidine) is a sympatholytic drug.[1]
See also
- Phenoxybenzamine
References
- ^ Prichard BN, Johnston AW, Hill ID, Rosenheim ML (January 1968). "Bethanidine, Guanethidine, and Methyldopa in Treatment of Hypertension: a Within-patient Comparison". British Medical Journal. 1 (5585): 135–44. doi:10.1136/bmj.1.5585.135. PMC 1984601. PMID 20791420.
- v
- t
- e
(antagonize α-adrenergic
vasoconstriction)
Central |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Peripheral |
|
Serotonin receptor antagonists | |
---|---|
Endothelin receptor antagonists (for PHTooltip Pulmonary hypertension) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e